A detailed history of Orbimed Advisors LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 6,943,654 shares of CRVS stock, worth $33.3 Million. This represents 0.86% of its overall portfolio holdings.

Number of Shares
6,943,654
Previous 6,943,654 -0.0%
Holding current value
$33.3 Million
Previous $12.6 Million 190.12%
% of portfolio
0.86%
Previous 0.3%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$1.89 - $8.53 $2.1 Million - $9.47 Million
-1,109,644 Reduced 13.78%
6,943,654 $33.6 Million
Q1 2021

May 17, 2021

BUY
$2.86 - $4.77 $3.68 Million - $6.13 Million
1,285,714 Added 19.0%
8,053,298 $24.8 Million
Q3 2019

Nov 14, 2019

BUY
$3.01 - $6.5 $607,715 - $1.31 Million
201,899 Added 3.08%
6,767,584 $20.4 Million
Q2 2019

Aug 14, 2019

BUY
$3.3 - $4.58 $1.97 Million - $2.74 Million
598,101 Added 10.02%
6,565,685 $24.6 Million
Q1 2018

May 15, 2018

BUY
$7.48 - $11.53 $4.4 Million - $6.78 Million
588,235 Added 10.94%
5,967,584 $68.8 Million
Q3 2017

Nov 14, 2017

BUY
$11.3 - $17.23 $60.8 Million - $92.7 Million
5,379,349
5,379,349 $85.7 Million

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.